Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Potential Value of a Negative Finding

The Potential Value of a Negative Finding EDITORIAL An Illustrative Example LINICAL TRIALS WITH POSITIVE FINDINGS In the prior study, 28.0% of participants in the vigaba- are more likely to be submitted and pub- trin group and 7.5% of the participants in the placebo lished than those with negative find- groups met the criteria for end-of-trial abstinence, a dif- ings, but negative findings can provide ference that could have been affected substantially by the C invaluable information, particularly when differential rates of retention in the 2 groups. This meth- based on sound methodology. The study by Somoza and odological limitation makes it difficult to determine colleagues in this issue provides a powerful illustration whether vigabatrin directly reduced cocaine use or of the potential value of a negative finding. whether it just affected retention in treatment. This is not to say that one study is correct and the other is incor- rect. Indeed, Somoza et al reported an effect on semi- See also page 630 quantitative benzoylecognine urinalysis results, which Somoza et al report the results of a clinical trial that provides some suggestion that vigabatrin may have af- evaluated the safety and efficacy of vigabatrin for treating fected cocaine use. However, the lack of an effect http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Psychiatry American Medical Association

The Potential Value of a Negative Finding

Loading next page...
 
/lp/american-medical-association/the-potential-value-of-a-negative-finding-XtgI9jVoRd

References (7)

Publisher
American Medical Association
Copyright
Copyright 2013 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-622X
eISSN
2168-6238
DOI
10.1001/jamapsychiatry.2013.1116
pmid
23575653
Publisher site
See Article on Publisher Site

Abstract

EDITORIAL An Illustrative Example LINICAL TRIALS WITH POSITIVE FINDINGS In the prior study, 28.0% of participants in the vigaba- are more likely to be submitted and pub- trin group and 7.5% of the participants in the placebo lished than those with negative find- groups met the criteria for end-of-trial abstinence, a dif- ings, but negative findings can provide ference that could have been affected substantially by the C invaluable information, particularly when differential rates of retention in the 2 groups. This meth- based on sound methodology. The study by Somoza and odological limitation makes it difficult to determine colleagues in this issue provides a powerful illustration whether vigabatrin directly reduced cocaine use or of the potential value of a negative finding. whether it just affected retention in treatment. This is not to say that one study is correct and the other is incor- rect. Indeed, Somoza et al reported an effect on semi- See also page 630 quantitative benzoylecognine urinalysis results, which Somoza et al report the results of a clinical trial that provides some suggestion that vigabatrin may have af- evaluated the safety and efficacy of vigabatrin for treating fected cocaine use. However, the lack of an effect

Journal

JAMA PsychiatryAmerican Medical Association

Published: Jun 1, 2013

There are no references for this article.